STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLSI
  4. [Form 4] TriSalus Life Sciences, Inc. Insider Trading Activity

[Form 4] TriSalus Life Sciences, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TriSalus Life Sciences (TLSI) reported new equity awards to its CEO and President, Mary Szela, in a Form 4 filing. She received 125,000 performance stock units (PSUs) on 02/13/2024 that vest upon achieving or exceeding $50 million of revenue over any 12‑month period ending on or before February 28, 2027. On 11/24/2025 she was granted 125,000 restricted stock units that vest in four equal annual installments starting November 24, 2025.

Also on 11/24/2025, she received 300,000 additional PSUs tied to achieving or exceeding $75 million of revenue over any 12‑month period ending on or before December 31, 2027, with 150,000 vesting upon achievement and 150,000 vesting one year later. She was further granted an option to buy 250,000 shares at $5.55 per share, expiring on 11/23/2035, vesting over four years. After these transactions, she beneficially owns 742,802 common shares and 1,578,182 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Szela Mary T
Role CEO and President
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 250,000 $0.00 --
Grant/Award Common Stock 125,000 $0.00 --
Grant/Award Common Stock 300,000 $0.00 --
Grant/Award Common Stock 125,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 1,578,182 shares (Direct); Common Stock — 442,802 shares (Direct)
Footnotes (1)
  1. Represents the granting of Performance Stock Units (PSUs) upon achieving or exceeding $50 million of revenue over any 12 consecutive calendar month period ending on or before February 28, 2027. The PSUs vest immediately upon achieving the performance requirement, subject to the continued employment through each respective vesting date. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date. Represents the granting of PSUs upon achieving or exceeding $75 million of revenue over any 12 consecutive calendar month period ending on or before December 31, 2027. 150,000 PSUs vest immediately upon achieving the performance requirement and 150,000 PSUs vest on the one-year anniversary of achieving the performance requirement, subject to the continued employment through each respective vesting date. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Szela Mary T
(Last) (First) (Middle)
6272 W. 91ST AVENUE
(Street)
WESTMINSTER CO 80031
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and President
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2024 A 125,000(1) A $0 317,802 D
Common Stock 11/24/2025 A 125,000(2) A $0 442,802 D
Common Stock 11/24/2025 A 300,000(3) A $0 742,802 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $5.55 11/24/2025 A 250,000 (4) 11/23/2035 Common Stock 250,000 $0 1,578,182 D
Explanation of Responses:
1. Represents the granting of Performance Stock Units (PSUs) upon achieving or exceeding $50 million of revenue over any 12 consecutive calendar month period ending on or before February 28, 2027. The PSUs vest immediately upon achieving the performance requirement, subject to the continued employment through each respective vesting date.
2. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.
3. Represents the granting of PSUs upon achieving or exceeding $75 million of revenue over any 12 consecutive calendar month period ending on or before December 31, 2027. 150,000 PSUs vest immediately upon achieving the performance requirement and 150,000 PSUs vest on the one-year anniversary of achieving the performance requirement, subject to the continued employment through each respective vesting date.
4. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.
Remarks:
/s/ Mary Szela 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR